SOLITRON DEVICES, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS
SOLITRON DEVICES INC (SODI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_985975.htm EXHIBIT 99.1 ex_985975.htm Exhibit 99.1 SOLITRON DEVICES, INC. ANNOUNCES FISCAL 2027 FIRST QUARTER RESULTS WEST PALM BEACH, FL – Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce fiscal 2027 first quarter results.
How this was made
The 30-second read
Why it matters
Traders can update models using the reported quarter’s sales, bookings, backlog, and profitability, and they can reassess catalyst timing around the next AMRAAM order (expected in fiscal Q3) plus the strategic alternatives review.
Market read
Fresh quarterly financials and backlog dynamics, plus a stated procurement-related expectation and a strategic alternatives process, create actionable updates for position sizing and catalyst tracking.
What to watch
Net income was influenced by a $0.33M contingent consideration increase tied to an earn-out payment, and backlog excludes a $5.04M order received after quarter end, which can distort quarter-to-quarter comparability.
Background
The 8-K (Item 2.02) includes Exhibit 99.1 with fiscal 2027 first-quarter results for Solitron Devices, an OTC Pink-listed defense component supplier.
Ticker impact
Solitron reported fiscal 2027 Q1 net sales up 101% to about $5.44M, with net income of $0.99M and backlog up 28% to $23.34M.
Near-term bias positive on improved revenue, profitability, and rising backlog, but with uncertainty around bookings and timing of the next AMRAAM order.
The article includes multiple new datapoints (sales, net income, bookings, backlog, contingent consideration impact) and a new corporate process (retained an investment banker for strategic alternatives), which can re-rate risk and valuation, though OTC liquidity and procurement timing add uncertainty.
Market effects
Defense electronics suppliers may see read-across interest if AMRAAM production increases are pursued, but congressional approval risk remains.
No clear regional market linkage beyond the company’s defense supply chain.
Limited global relevance; story is primarily US defense procurement and a single microcap’s quarterly performance.
Counterpoint
Lower net bookings (-48% to $1.45M) despite higher backlog suggests near-term demand conversion risk, and the AMRAAM order timing is only an expectation, not a contract.
Key entities
- companySOLITRON DEVICES, INC.
Reported fiscal 2027 first-quarter results, backlog changes, and retained an investment banker to explore strategic alternatives.
- contractual_itemMEI earn out
Contingent consideration increased by $0.33M due to an MEI earn-out payment tied to a large order received after quarter end.
- government_procurementU.S. Air Force AMRAAM production request
Unfunded priorities list reportedly requests increasing AMRAAM production from 1,200 annually to 2,400 by 2028, which Solitron supplies.
